Bristol-Myers to Buy Celgene in $74 Billion Cancer-Drug Bet
Bristol-Myers Squibb Co. brand medication sits on a pharmacy shelf in Provo, Utah, U.S. (Photographer: George Frey/Bloomberg)

Bristol-Myers to Buy Celgene in $74 Billion Cancer-Drug Bet

(Bloomberg) -- Bristol-Myers Squibb agreed to acquire Celgene Corp. in a record-sized $74 billion deal that will unite two drugmakers battling for advantage in a crowded market for innovative cance...
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.